Search

Your search keyword '"Li, L.X."' showing total 225 results
Start Over Author "Li, L.X."
225 results on '"Li, L.X."'

14. Random vibration analysis of an uncertain vehicle-track coupled system based on a polynomial dimensional decomposition

Author

Liu, F., Zhao, Y., Li, L.X., and Xiao, J.

Abstract

ABSTRACTIn this paper, the uncertainty propagation of an uncertain vehicle-track coupled system (VTCS) subjected to track irregularity is quantified using a polynomial-dimensional decomposition (PDD). Firstly, the conditional power spectral density (PSD) of response related to uncertain parameters is derived using the pseudo-excitation method. Secondly, the PDD surrogate model that can describe the probabilistic characters of the uncertainty propagation is established by conducting the dimensional decomposition to the conditional PSD with component functions and performing the Fourier expansion to the component functions. Finally, the dimensional reduction integration and Gauss integration are introduced to overcome the difficulty of high-dimensional integration when calculating the expansion coefficients. In numerical example, the proposed method is applied to the uncertainty quantification of vertical vibration response of an uncertain VTCS, the accuracy and efficiency of the proposed method are verified by comparing the results of the PDD method with that of Monte-Carlo simulation.

Published
2024
Full Text
View/download PDF

22. Low risk of hyperprogression with first-line chemoimmunotherapy for advanced non-small cell lung cancer: pooled analysis of 7 clinical trials

Author

Li, L.X. (Lee X.), Cappuzzo, F. (Federico), Matos, I. (Ignacio), Socinski, M.A. (Mark A.), Hopkins, A.M. (Ashley M.), and Sorich, M.J. (Michael J.)

Subjects
Hyperprogression, Hyperprogressive disease, Non-small cell lung cancer, Immune checkpoint inhibitor, Chemoimmunotherapy
Abstract

Background Monotherapy immune checkpoint inhibitor (ICI) used in second- or later-line settings has been reported to induce hyperprogression. This study evaluated hyperprogression risk with ICI (atezolizumab) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer (NSCLC), and provides insights into hyperprogression risk with contemporary first-line ICI treatment. Methods Hyperprogression was identified using Response Evaluation Criteria in Solid Tumours (RECIST)-based criteria in a dataset of pooled individual-participant level data from BIRCH, FIR, IMpower130, IMpower131, IMpower150, OAK, and POPLAR trials. Odds ratios were computed to compare hyperprogression risks between groups. Landmark Cox proportional-hazard regression was used to evaluate the association between hyperprogression and progression-free survival/overall survival. Secondarily, putative risk factors for hyperprogression among second- or later-line atezolizumab-treated patients were evaluated using univariate logistic regression models. Results Of the included 4644 patients, 119 of the atezolizumab-treated patients (n = 3129) experienced hyperprogression. Hyperprogression risk was markedly lower with first-line atezolizumab-either chemoimmunotherapy or monotherapy-compared to second/later-line atezolizumab monotherapy (0.7% vs. 8.8%, OR = 0.07, 95% CI, 0.04-0.13). Further, there was no statistically significant difference in hyperprogression risk with first-line atezolizumab-chemoimmunotherapy versus chemotherapy alone (0.6% vs. 1.0%, OR = 0.55, 95% CI, 0.22-1.36). Sensitivity analyses using an extended RECIST-based criteria including early death supported these findings. Hyperprogression was associated with worsened overall survival (HR = 3.4, 95% CI, 2.7-4.2, P < .001); elevated neutrophil-to-lymphocyte ratio was the strongest risk factor for hyperprogression (C-statistic = 0.62, P < .001). Conclusions This study presents first evidence for a markedly lower hyperprogression risk in advanced NSCLC patients treated with first-line ICI, particularly with chemoimmunotherapy, as compared to second- or later-line ICI treatment. This study evaluated hyperprogression risk with the use of immune checkpoint inhibitor (ICI) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer, providing insight into hyperprogression risk with contemporary first-line ICI treatment.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results